NCX
Beyond's analysis on NCX
- — Ocumension files NDA in China for Nicox’s NCX 470 glaucoma therapy, marking a key regulatory milestone for the ophthalmic asset
- — Nicox and partner Ocumension submit NDA for NCX 470 in China, targeting approval for a novel nitric oxide-donating glaucoma therapy
Recent news mentioning NCX
- — Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
- — Nicox annonce la soumission d’une NDA pour NCX 470 en Chine par son partenaire Ocumension